HeimJAZZ • NASDAQ
add
Jazz Pharmaceuticals PLC
140,22 $
Eftir lokun(0,00%)0,00
140,22 $
Lokað: 3. mar., 17:20:00 GMT-5 · USD · NASDAQ · Lagalegir fyrirvarar
Við síðustu lokun
143,53 $
Dagbil
139,60 $ - 145,40 $
Árabil
99,06 $ - 148,06 $
Markaðsvirði
8,48 ma. USD
Meðalmagn
788,34 þ.
V/H-hlutf.
16,21
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | des. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 1,09 ma. | 7,53% |
Rekstrarkostnaður | 768,69 m. | 9,42% |
Nettótekjur | 191,12 m. | 102,98% |
Hagnaðarhlutfall | 17,56 | 88,82% |
Hagnaður á hvern hlut | 6,60 | 31,47% |
EBITDA | 396,98 m. | 0,82% |
Virkt skatthlutfall | -43,48% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | des. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 2,99 ma. | 83,66% |
Heildareignir | 12,01 ma. | 5,43% |
Heildarskuldir | 7,92 ma. | 3,42% |
Eigið fé alls | 4,09 ma. | — |
Útistandandi hlutabréf | 60,73 m. | — |
Eiginfjárgengi | 2,13 | — |
Arðsemi eigna | 4,71% | — |
Ávöxtun eigin fjár | 5,54% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | des. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 191,12 m. | 102,98% |
Handbært fé frá rekstri | 398,58 m. | 138,19% |
Reiðufé frá fjárfestingum | -193,29 m. | -289,87% |
Reiðufé frá fjármögnun | -8,28 m. | 91,75% |
Breyting á handbæru fé | 194,73 m. | 14,13% |
Frjálst peningaflæði | 466,32 m. | 470,30% |
Um
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Framkvæmdastjóri
Stofnsett
2003
Vefsvæði
Starfsfólk
2.800
